Medsciences Capital

What is Medsciences Capital?

MedSciences Capital (MSC) is a dedicated venture capital investment firm founded in the year 2000, with its headquarters located in The Hague, Netherlands. They specialize in both early-stage and later-stage investments, targeting companies that are developing innovative products within the life sciences and health sectors.

Their investment thesis revolves around the belief that scientific breakthroughs and technological advancements can drive significant improvements in medical and healthcare outcomes. As active investors, they not only provide financial support but also share their specialized sector experience with the companies in their portfolio to help guide growth and development.

MedSciences Capital manages several portfolios, which include MSC I, MSC II, and the MedSciences Seed Fund—a TechnoPartner supported seed fund particularly attentive to emerging ventures. Furthermore, MedSciences Capital is in the process of launching a new fund, MSC III, which is indicative of their ongoing commitment to fostering innovation within the medical life sciences sector. The firm's current portfolio displays a range of promising enterprises such as Akkolens International, Kiadis Pharma, MacroZyme, and others who are on the cutting-edge of their respective fields, from biotechnology to medical devices and hospital services.

By investing in these areas, MSC aspires to make meaningful contributions to the betterment of health services globally. Their website also mentions an active engagement with cookies to enhance user experience, which signals their attention to details not only in their investment approaches but also in maintaining their digital presence for clients and stakeholders.

What they say:

We are a venture capital provider.

What we look for: We invest in early- and mid-stage companies developing innovative products, likely in life sciences.